ENvue Medical FEED

NASDAQ FEED
$0.42 -0.01 (-1.49%)
At close: Aug 19, 2026 · 4:00 PM UTC
Financial Ratios
Market Cap1.40 Mn
P/E-0.03
P/S0.73
Div. Yield0.00
ROIC (Qtr)-0.09
Total Debt (Qtr)2.16 Mn
Revenue Growth (1y) (Qtr)-51.62
Add ratio to table…

About

NanoVibronix, Inc. develops, manufactures, and markets noninvasive ultrasound based products for biofilm prevention, pain therapy, and wound healing as well as enteral feeding systems for hospital patients. The company operates through two wholly owned subsidiaries: NanoVibronix Ltd. which does business as Nano OpCo and Envizion Holdings LLC which does business as Envizion. Nano OpCo concentrates on devices that use low frequency ultrasound to prevent bacterial biofilm on…

Read more ↓
Sector: Healthcare Sector rationale The company designs and manufactures medical devices, specifically ultrasound-based products for biofilm prevention, pain therapy, and wound healing (UroShield, PainShield, WoundShield), as well as enteral feeding systems (Envizion). Its primary customers are hospitals, pharmacies, and clinics, and its revenue is derived from the sale of these medical devices and their associated disposable components. Industries: Medical Devices Healthcare Primary The company designs and manufactures therapeutic and surgical medical devices, specifically ultrasound-based products like UroShield for biofilm prevention, PainShield for pain therapy, and the Envizion System for guiding feeding tube placement. These are regulated treatment devices sold to hospitals and distributors. Medical Supplies Healthcare Secondary The company generates recurring revenue from the sale of medical supplies and consumables, specifically disposable feeding tubes for the Envizion system and disposable transducers and patches for the Nano OpCo devices. Classified using BQ-MICS CIK: 0001326706

Investment Thesis

▲ Bull case
  • Ohmium International is strategically positioning itself at the forefront of the global green hydrogen value chain through its master cooperation agreement with Hynfra, which targets high-potential projects in Mauritania, Jordan, and Oman—regions with exceptional solar and wind resources that enable low-cost renewable power generation essential for economical green hydrogen production. The focus on Front-End Engineering and Design (FEED) stages indicates these projects are advancing beyond conceptual phases into detailed planning, reducing execution risk and increasing the likelihood of final investment decisions. Ohmium’s provision of technical support and PEM electrolyzer expertise throughout development ensures deeper integration into project lifecycles, potentially leading to preferred supplier status and follow-on equipment orders as projects move into engineering, procurement, and construction (EPC) phases. This early involvement allows Ohmium to influence technology selection and secure long-term revenue streams tied to project milestones, rather than relying solely on one-time equipment sales. The emphasis on RFNBO-compliant green ammonia for export to European markets aligns with stringent EU regulations under the Renewable Energy Directive II (RED II), creating a premium market opportunity where compliance-certified hydrogen carries significant value, especially as Europe seeks to decarbonize hard-to-abate sectors like shipping and industry. Given Ohmium’s existing pipeline exceeding 2 GW across three continents, this partnership significantly expands its geographic footprint into the MENA region—a zone increasingly prioritized by international financiers and development banks for green hydrogen investments due to policy support and resource advantages. The modular nature of Ohmium’s PEM electrolyzers enables rapid scalability and phased deployment, matching the typical development trajectory of large-scale green ammonia projects that often begin with pilot stages before full build-out, thereby reducing upfront capital risk for clients and accelerating adoption. Furthermore, Hynfra’s deliberate strategy of maintaining at least two qualified suppliers per technology category validates Ohmium’s credibility as a trusted partner, suggesting the company has passed rigorous technical and commercial due diligence, which could lead to inclusion in other Hynfra-led projects across its expanding pipeline in Europe, Asia, and Africa. With Ohmium having secured $250 Million in Series C financing led by TPG Rise Climate in 2023, the company possesses strong balance sheet flexibility to invest in project development activities, potentially co-investing or taking equity stakes in promising ventures, thereby shifting from a pure equipment supplier to a value-integrated participant in the green hydrogen economy.
▼ Bear case
  • Despite the optimistic framing of the cooperation agreement, Ohmium International faces substantial execution risks in the Mauritania, Jordan, and Oman projects that are not adequately addressed in the announcement, particularly regarding the availability of affordable renewable energy infrastructure and water resources—two critical inputs for green hydrogen production that remain underdeveloped in these host countries. While the news highlights abundant solar and wind potential, it omits any discussion of grid readiness, transmission capacity, or planned investments in dedicated renewable energy parks needed to power electrolyzers at scale, leaving a significant gap between resource potential and actual project viability. Similarly, water access for electrolysis—a process requiring approximately 9 liters of ultra-pure water per kilogram of hydrogen—is not mentioned, raising concerns about feasibility in arid regions like Mauritania and Oman where freshwater scarcity could necessitate costly desalination, substantially increasing operational expenditures and undermining the cost-competitiveness of green hydrogen. The focus on FEED stages also implies these projects are still years away from revenue generation, with no timelines provided for when front-end work will conclude or when financial close might occur, exposing Ohmium to prolonged periods of sunk costs in engineering support without guaranteed equipment orders. Furthermore, the emphasis on exporting RFNBO-compliant green ammonia to Europe introduces dependency on evolving regulatory frameworks and potential trade barriers; any delays in EU certification processes, changes to subsidy mechanisms like the Carbon Border Adjustment Mechanism (CBAM), or shifts in European demand due to economic slowdowns could severely impact project economics. Ohmium’s reliance on third-party developers like Hynfra for project origination means it lacks control over critical path items such as permitting, land acquisition, and offtake agreement finalization—factors that frequently delay or derail green hydrogen initiatives despite strong technology readiness. The company’s global pipeline exceeding 2 GW remains largely at early stages of development, with limited visibility into how much capacity is backed by binding offtake contracts or secured financing, suggesting a significant portion may never reach financial close. Additionally, while Ohmium raised $250 Million in 2023, the capital-intensive nature of scaling manufacturing and supporting project development could lead to rapid cash burn if project timelines slip, especially given the nascent state of the green hydrogen market and the absence of widespread commercial-scale operations to date. Finally, the competitive landscape for PEM electrolyzers is intensifying, with established industrial players and new entrants rapidly expanding capacity, potentially pressuring Ohmium’s pricing power and market share even if it secures technical wins in FEED stages.

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 ABT Abbott Laboratories 196.58 Bn36.244.2232.61 Bn
2 SYK Stryker Corp 127.35 Bn34.154.9314.94 Bn
3 MDT Medtronic plc 118.25 Bn24.443.2527.96 Bn
4 BSX Boston Scientific Corp 74.32 Bn20.223.5412.62 Bn
5 EW Edwards Lifesciences Corp 52.61 Bn2,104.558.080.60 Bn
6 DXCM Dexcom Inc 34.26 Bn34.276.90-
7 GEHC GE HealthCare Technologies Inc. 32.92 Bn16.051.5510.10 Bn
8 SNN Smith & Nephew Plc 26.16 Bn156.664.313.21 Bn